

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review


SUPPLEMENTARY MATERIALS

Supplementary Table 1: Quality analysis of included studies


Index	No. 1	No. 2	No. 3	No. 4	No. 5	No. 6	No. 7	No. 8	No. 9	No. 10	No. 11	No. 12	No. 13	No. 14	No. 15
Was the method of randomization adequate?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Was the treatment allocation concealed?	U	U	Y	U	U	U	Y	Y	U	N	N	Y	N	Y	Y
Were the groups similar at baseline regarding the most important prognostic indicators?	Y	U	Y	Y	Y	U	Y	Y	U	Y	U	Y	Y	Y	N
Was the patient blinded to the intervention?	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Was the care provider blinded to the intervention?	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Was the outcome assessor blinded to the intervention?	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Were co-interventions avoided or similar?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Was the compliance acceptable in all groups?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Was the drop-out rate described and acceptable?	Y	Y	Y	Y	Y	Y	U	Y	Y	Y	U	Y	Y	Y	U
Was the timing of the outcome assessment in all groups similar?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
Did the analysis include an intention-to-treat analysis?	Y	U	Y	Y	Y	Y	U	Y	Y	Y	U	Y	Y	Y	N

Notes: Y = Yes; N = No; U = Unclear.


Study: No.1 = Albain *et al.*; No.2 = Amadori *et al.*; No.3 = Brufsky *et al.*; No.4 = Chan *et al.*; No.5 = Fountzilias *et al.*; No.6 = Gómez *et al.*; No.7 = Joensuu *et al.*; No.8 = Martín *et al.*; No.9 = Nielsen *et al.*; No.10 = Pallis *et al.*; No.11 = Papadimitriou *et al.*; No.12 = Park *et al.*; No.13 = Swain *et al.*; No.14 = Vici *et al.*; No.15 = Zielinski *et al.*




Supplementary Figure 1: Comparisons of progression free survivals between 2 arms after excluding the study with the high risk of bias (Zielinski *et al.*).



Supplementary Figure 2: Comparisons of objective tumor response rate between 2 arms after excluding the study with the high risk of bias (Zielinski *et al.*).



Supplementary Figure 3: Comparisons of objective tumor response rate between 2 arms with random-model.



Supplementary Figure 4: Funnel plots of objective tumor response rate between patients with gemcitabine-containing regimens and patients with non- gemcitabine-containing regimens (Egger's tests).